Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

TNBC - Triple-Negative Breast Cancer Clinical Trial

Official title:

A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05402722
• Other study ID #: breast-202204
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2022
• Est. completion date: June 30, 2023

Study information

• Verified date: January 2022
• Source: Beijing 302 Hospital
• Contact: xiaobo wang, doctor
• Phone: +86-010-66947250
• Email: 724292466[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: June 30, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The patients sign the written informed consent.

2. Women aged 18-75.

3. The pathologic diagnosis of unresectable recurrent or metastatic triple-negative breast cancer [ER-negative(IHC<1%), PR-negative(IHC<1%), HER2-negative(IHC-/+ or IHC++ and FISH/CISH-)]. Patients with at least one measuring lesion that was conformed to RECIST v1.1 standard.

4. PD-1/PD-L1positive or TMB=5.

5. Prior therapy (adjuvant/neoadjuvant/advanced) must have included an anthracycline and/or a taxane in any combination or order and either in the early or metastatic disease setting unless contraindicated for a given patient.

6. Eastern Cooperative Oncology Group (ECOG) performance status of = 1.

7. The results of patient's blood tests are as follows:

• Hb=90g/L; • Plt=100^9/L; • Serum albumin =3g/dL;• Neutrophils=1.5^9/L; TSH= normal upper limit (ULN);• ALT and AST =1.5 ULN (liver metastases =3 ULN); • TBIL =ULN (total bilirubin =1.5 ULN in Gilbert's syndrome or liver metastasis subjects);• ALT and AST =1.5 ULN (liver metastases =3 ULN);• AKP= 2.5 ULN; • Renal function within 7 days before the first administration: serum creatinine =1.5 ULN or creatinine clearance =60mL/min

8. Female subjects of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose and must be willing to use very efficient barrier methods of contraception for the course of the study through 6 months after the last dose of study treatment.

Exclusion Criteria:

1. The subjects had a central nervous system metastases with clinical symptoms.

2. Subjects with treatment history of PD-1 / PD-L1 inhibitors;

3. Peripheral neuropathy = grade 2; Cardiac dysfunction, hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis and tuberculosis; Autoimmune diseases requiring systemic treatment, and a history of pneumonia (requiring corticosteroid treatment) or interstitial lung disease.

4. Pregnant or lactating women.

5. Other clinical trials of drugs were used in the first four weeks before the first dose.

6. The subjects had any history of autoimmune disease or any use of systemic glucocorticoid or immunosuppressive medications.

7. Hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.).

8. Congenital or acquired immune deficiency (such as HIV infection);

9. Receive live vaccine within 4 weeks before or during the study period;

10. Patients who are allergic to or contraindicated to the experimental drugs.

11. Other malignant tumors in the past, except cervical cancer and non melanoma skin cancer, which have survived for 5 years without disease.

12. Subjects with any other diseases that are unfit for the treatment.

Related Conditions & MeSH terms

• Breast Neoplasms
• TNBC - Triple-Negative Breast Cancer
• Triple Negative Breast Neoplasms

Intervention

Drug:
• Eribulin
Eribulin Mesylate,1.4mg/m2,Intravenous infusion,d1,d8,3-week cycle
• anti-PD-1 antibody
Sintilimab Injection,Intravenous infusion,200mg,3-week cycle

Locations

Country	Name	City	State
China	The Fifth Medical Center of PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing 302 Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival,PFS	The time from the date of randomization to the date of first documented progression or date of death from any cause, whichever came first.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months
Secondary	Number of participants with Adverse Events	Adverse Events are monitored throughout the trial and for 30 days after discontinuation of treatment (90 days for serious adverse events) and graded according to the Common Terminology Criteria for Adverse Events, version 4.0, of the National Cancer Institute.	From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months
Secondary	the correlation between the expression of PD-L1 of circulating tumor cells and prognosis	To detect the differences of the expression of PD-L1 in patients with different curative effects and prognosis,including the number of circulating tumor cells,and PD-L1 expression or others.	From one week before treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 10 months